Log in to search using one of your social media accounts:

 

Empa-kidney
EMPA-KIDNEY (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

Investment of 65 million euro in avian vaccines in France
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

New Partnership to develop novel checkpoint inhibitor
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 4, 2018 Category: Research Source Type: news

Results from landmark DYNAGITO trial
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Boehringer Ingelheim announces 2018 BVDzero Case Awards
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Joint Venture Targeting Foot-and-Mouth Disease in China
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 26, 2018 Category: Research Source Type: news

EHRA Congress 2018
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2018 Category: Research Source Type: news

FDA_Fast_Track_Designation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 19, 2018 Category: Research Source Type: news

Expanded asthma indication for SPIRIVA RESPIMAT in EU
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2018 Category: Research Source Type: news

Expansion of Cancer Research with Vanderbilt University
Expansion of Cancer Research with Vanderbilt University (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 13, 2018 Category: Research Source Type: news

EMPERIAL heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 5, 2018 Category: Research Source Type: news

IPFwhywait
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 28, 2018 Category: Research Source Type: news

PRRS Research Award open for submissions until July 1st
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 20, 2018 Category: Research Source Type: news

Systemic Sclerosis World Congress
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 14, 2018 Category: Research Source Type: news

PDE9 Inhibition in AD
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 9, 2018 Category: Research Source Type: news

2018 Ruminant Well-Being Awards open for application
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 15, 2018 Category: Research Source Type: news

BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2018 Category: Research Source Type: news

BIVF funding more than doubled to 250 M €
BIVF funding more than doubled to 250 M € (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2018 Category: Research Source Type: news

Collaboration with Roche in Immunology
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 19, 2017 Category: Research Source Type: news

Collaboration with Autifony in CNS
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2017 Category: Research Source Type: news

Change in board of managing directors
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 15, 2017 Category: Research Source Type: news

GiotagStudy
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 12, 2017 Category: Research Source Type: news

Progress in immuno-oncology partnerships in 2017
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 11, 2017 Category: Research Source Type: news

Publication notice for the contribution of its Animal Health Business of Boehringer Ingelheim France SAS to Merial SAS
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 1, 2017 Category: Research Source Type: news

Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows
European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat®
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF
New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat® in asthma
Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat® in asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Respimat ® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim
Respimat ® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Vargatef ® (nintedanib) approved in the EU for NSCLC
Vargatef ® (nintedanib) approved in the EU for NSCLC (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union
Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New GIOTRIF ® data published in The Lancet Oncology
New GIOTRIF ® data published in The Lancet Oncology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

GIOTRIF ® Asian EGFR M+ NSCLC subgroup analysis
GIOTRIF ® Asian EGFR M+ NSCLC subgroup analysis (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New advance in COPD maintenance treatment, Spiolto ® Respimat®, approved in first European countries
New advance in COPD maintenance treatment, Spiolto ® Respimat®, approved in first European countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat®
Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA approves Boehringer Ingelheim ’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
FDA approves Boehringer Ingelheim ’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy
New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund
Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: new indication for Spiriva ® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
Asthma: new indication for Spiriva ® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD "
" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention
Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented at the ESC Congress 2014
New Pradaxa ® data to be presented at the ESC Congress 2014 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela ® in Europe
Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela ® in Europe (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news